Available IPD datapackage for study 'A 52-week, Randomised, Multi-centre, Parallel Group Study to Investigate the Safety and Efficacy of BI 10773 (10 mg or 25 mg Administered Orally Once Daily) as add-on Therapy to an Oral Antidiabetic Drug (Sulfonylurea, Biguanide, Thiazolidinedione, Alpha Glucosidase Inhibitor, DPP-IV Inhibitor, or Glinide) in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control'
View DatasetBoehringer Ingelheim
Description
The objective of the study is to investigate the long-term safety and efficacy of BI 10773 given for 52 weeks as add-on therapy to one oral antidiabetic drug in patients with type 2 diabetes mellitus with insufficient glycaemic control.
Citations (0)
No citations found
It looks like this dataset has no citations.
Mentions (0)
No mentions found
It looks like this dataset has not been mentioned in any sources.
Metrics Over Time
Publication Details
DOI
Publisher
Vivli
License
Study data may be accessed by completing a request form at https://vivli.org. It will then be reviewed according to the data contributor’s governance policy, see https://vivli.org/members/ourmembers/ for Vivli member’s review process. If approved, use of the data is governed by the data use agreement at https://vivli.org/resources/vivli-data-use-agreement/
Subfield
Pharmacology
Field
Medicine
Domain
Health Sciences
Confidence Score
86%
Source
Open Alex
Keywords
Conditions: Diabetes Mellitus, Type 2Interventions: MetforminInterventions: BI 10773Interventions: Placebo (low dose)Interventions: Placebo (high dose)